Adaptimmune Therapeutics Plc (ADAP) Stock
ADAP is no longer traded. Adaptimmune Therapeutics Plc was delisted from the Nasdaq in November 2025.
Prices on this page are historical; the last trade was November 5, 2025 at $0.04.
Adaptimmune Therapeutics Plc stock price history
ADAP final trading statistics
- Final close
- $0.04
- Final trading day
- Nov 5, 2025
- Market cap at delisting
- $9.54M
- Shares outstanding
- 265.05M
- Final 52-week range
- $0.02 – $0.86
- Avg. volume (final 3 mo.)
- 102,414,229
- All-time high (split-adj.)
- $21.12 · Jun 2015
- All-time low (split-adj.)
- $0.04 · Nov 2025
- Return since IPO
- -99.8%
- Beta
- 2.49
- Book value / share
- -$0.27
- Price / book
- -0.13
Adaptimmune Therapeutics Plc annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $178.03M | -$70.8M | $0.00 |
| FY2023 | $60.28M | -$113.9M | -$0.66 |
| FY2022 | $27.15M | -$165.5M | -$1.00 |
| FY2021 | $6.15M | -$158.1M | -$1.02 |
| FY2020 | $3.96M | -$130.1M | -$0.96 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics Plc stock FAQ
What happened to Adaptimmune Therapeutics Plc stock?
Adaptimmune Therapeutics Plc stock was delisted from the Nasdaq. Its final close was $0.04 on November 5, 2025.
Is ADAP stock still trading?
No. ADAP was delisted from the Nasdaq in November 2025 and no longer trades on a U.S. exchange.
What was the last price of ADAP stock?
ADAP closed at $0.04 on its final trading day, November 5, 2025, for a market value of about $9.54M.
What were Adaptimmune Therapeutics Plc's revenue and earnings in its last full fiscal year?
Adaptimmune Therapeutics Plc reported revenue of $178.03M and net income of -$70.8M in fiscal 2024, its last full year as a public company.
When did Adaptimmune Therapeutics Plc go public?
Adaptimmune Therapeutics Plc stock began trading on May 6, 2015.